JP2018529634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529634A5 JP2018529634A5 JP2018501163A JP2018501163A JP2018529634A5 JP 2018529634 A5 JP2018529634 A5 JP 2018529634A5 JP 2018501163 A JP2018501163 A JP 2018501163A JP 2018501163 A JP2018501163 A JP 2018501163A JP 2018529634 A5 JP2018529634 A5 JP 2018529634A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- monoclonal antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 61
- 239000012634 fragment Substances 0.000 claims description 60
- 239000000427 antigen Substances 0.000 claims description 47
- 102000036639 antigens Human genes 0.000 claims description 47
- 108091007433 antigens Proteins 0.000 claims description 47
- 208000018737 Parkinson disease Diseases 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 10
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 10
- 208000015872 Gaucher disease Diseases 0.000 claims description 6
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 6
- 208000032859 Synucleinopathies Diseases 0.000 claims description 6
- 210000004558 lewy body Anatomy 0.000 claims description 5
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000002567 autonomic effect Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000003802 alpha-Synuclein Human genes 0.000 description 25
- 108090000185 alpha-Synuclein Proteins 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001690 micro-dialysis Methods 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 102000019355 Synuclein Human genes 0.000 description 2
- 108050006783 Synuclein Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 241000272814 Anser sp. Species 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021136539A JP7138322B2 (ja) | 2015-07-13 | 2021-08-24 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2022136108A JP7608404B2 (ja) | 2015-07-13 | 2022-08-29 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2024221962A JP2025041734A (ja) | 2015-07-13 | 2024-12-18 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1512203.9A GB201512203D0 (en) | 2015-07-13 | 2015-07-13 | Agents,uses and methods |
| GB1512203.9 | 2015-07-13 | ||
| PCT/EP2016/066476 WO2017009312A1 (en) | 2015-07-13 | 2016-07-12 | Agents, uses and methods for the treatment of synucleinopathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021136539A Division JP7138322B2 (ja) | 2015-07-13 | 2021-08-24 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529634A JP2018529634A (ja) | 2018-10-11 |
| JP2018529634A5 true JP2018529634A5 (enExample) | 2019-08-15 |
| JP7012004B2 JP7012004B2 (ja) | 2022-02-10 |
Family
ID=54013851
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501163A Active JP7012004B2 (ja) | 2015-07-13 | 2016-07-12 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2021136539A Active JP7138322B2 (ja) | 2015-07-13 | 2021-08-24 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2022136108A Active JP7608404B2 (ja) | 2015-07-13 | 2022-08-29 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2024221962A Pending JP2025041734A (ja) | 2015-07-13 | 2024-12-18 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021136539A Active JP7138322B2 (ja) | 2015-07-13 | 2021-08-24 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2022136108A Active JP7608404B2 (ja) | 2015-07-13 | 2022-08-29 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2024221962A Pending JP2025041734A (ja) | 2015-07-13 | 2024-12-18 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
Country Status (40)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201512203D0 (en) * | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| EP3541836A1 (en) | 2016-11-15 | 2019-09-25 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| US11325968B2 (en) | 2016-12-16 | 2022-05-10 | H. Lundbeck A/S | Alpha-synuclein antibodies |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| BR112019013953A2 (pt) | 2017-01-06 | 2020-02-11 | Abl Bio Inc. | Anticorpo anti-a-syn e uso do mesmo |
| SG11201906947SA (en) | 2017-02-17 | 2019-08-27 | Bristol Myers Squibb Co | Antibodies to alpha-synuclein and uses thereof |
| KR20230144123A (ko) * | 2017-03-27 | 2023-10-13 | 체이스 테라퓨틱스 코포레이션 | 시누클레인병변을 치료하기 위한 조성물 및 방법 |
| US11220538B2 (en) | 2017-05-01 | 2022-01-11 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| EP3672635A4 (en) | 2017-08-23 | 2021-05-12 | The Trustees of The University of Pennsylvania | Monoclonal antibodies against pathological alpha-synuclein, and methods using same |
| CN111356701B (zh) * | 2017-11-17 | 2023-11-21 | Abl生物公司 | 抗α-突触核蛋白抗体及其用途 |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| EP3743918A1 (en) * | 2018-01-26 | 2020-12-02 | Quantum-Si Incorporated | Machine learning enabled pulse and base calling for sequencing devices |
| EP3752840A4 (en) * | 2018-02-12 | 2022-08-10 | The Scripps Research Institute | PROCEDURES RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES |
| JP7525474B2 (ja) * | 2018-08-09 | 2024-07-30 | エフ． ホフマン－ラ ロシュ アーゲー | パーキンソン病の判定 |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| KR20210154179A (ko) * | 2019-04-18 | 2021-12-20 | 에이씨 이뮨 에스.에이. | 치료 및 진단용 신규한 분자 |
| US20220226357A1 (en) * | 2019-04-29 | 2022-07-21 | Thomas Jefferson University | Methods for treating neurodegenerative disorders |
| CA3159964A1 (en) * | 2019-12-04 | 2021-06-10 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
| KR102466943B1 (ko) * | 2020-04-02 | 2022-11-14 | 한국과학기술연구원 | 갭을 갖는 바이오 센서를 이용한 파킨슨병 모니터링 방법 및 시스템 |
| CN111537738A (zh) * | 2020-05-18 | 2020-08-14 | 南通大学附属医院 | 用于超早期帕金森病检测的试剂盒 |
| AU2022337284A1 (en) * | 2021-09-01 | 2024-03-21 | Vaxxinity, Inc. | Methods for the prevention and treatment of synucleinopathies |
| EP4401770A2 (en) | 2021-09-16 | 2024-07-24 | H. Lundbeck A/S | Compositions and methods for treating synucleinopathies |
| CN117430686B (zh) * | 2022-07-22 | 2025-07-01 | 深圳市安群生物工程有限公司 | α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用 |
| WO2024177999A2 (en) * | 2023-02-21 | 2024-08-29 | The Regents Of The University Of Michigan | Human aggregated alpha-synuclein binding molecules |
| CN116077524A (zh) * | 2023-02-27 | 2023-05-09 | 广西馨海药业科技有限公司 | 氯化铷在制备治疗帕金森综合征的药物中的用途 |
| WO2025076635A1 (en) * | 2023-10-12 | 2025-04-17 | Universite Laval | Anti-alpha-synuclein antibodies and uses thereof |
| WO2025186235A1 (en) | 2024-03-05 | 2025-09-12 | H. Lundbeck A/S | Compositions and methods for treating multiple system atrophy (msa) |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB1512203A (en) | 1974-05-08 | 1978-05-24 | Aspin F | Rolls for use in profiling film |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988004777A1 (en) | 1986-12-15 | 1988-06-30 | Ultra Diagnostics Corporation | Monomeric phthalocyanine reagents |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| EP0804070B1 (en) | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| PT1150918E (pt) | 1999-02-03 | 2005-01-31 | Biosante Pharmaceuticals Inc | Metodo de fabrico de particulas terapeuticas de fosfato de calcio |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| NZ517372A (en) | 1999-07-29 | 2004-04-30 | Medarex Inc | Human monoclonal antibodies to HER2/neu |
| JP4093757B2 (ja) | 1999-08-24 | 2008-06-04 | メダレックス， インコーポレイテッド | ヒトｃｔｌａ−４抗体およびその使用 |
| EP1299411A4 (en) | 2000-07-07 | 2006-02-15 | Panacea Pharm Llc | METHOD FOR PREVENTING INJURY OF NEURAL TISSUE AND TREATING ALPHA SYNUCLEINE-RELATED DISEASES |
| WO2002043478A2 (en) | 2000-11-30 | 2002-06-06 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| US20020197258A1 (en) | 2001-06-22 | 2002-12-26 | Ghanbari Hossein A. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| US8829198B2 (en) | 2007-10-31 | 2014-09-09 | Proteotech Inc | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| WO2005013889A2 (en) | 2003-05-19 | 2005-02-17 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in lewy body disease |
| WO2005047860A2 (en) * | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| JP2006031250A (ja) | 2004-07-14 | 2006-02-02 | Fuji Xerox Co Ltd | 通信装置およびその制御方法 |
| EA013752B1 (ru) * | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
| US20060205024A1 (en) | 2005-03-08 | 2006-09-14 | Sun Health Research Institute | Method to diagnose and evaluate progression of Alzheimer's disease |
| US20080300204A1 (en) * | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
| BRPI0619056A2 (pt) | 2005-11-28 | 2011-09-20 | Genmab As | anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica |
| JP5558834B2 (ja) | 2007-02-23 | 2014-07-23 | ヤンセン アルツハイマー イミュノセラピー | シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置 |
| ES2570182T3 (es) | 2007-02-23 | 2016-05-17 | Prothena Biosciences Ltd | Prevención y tratamiento de la enfermedad sinucleinopática y amiloidogénica |
| ES2559859T3 (es) * | 2007-05-16 | 2016-02-16 | The Brigham And Women's Hospital, Inc. | Tratamiento de sinucleinopatías |
| EP3255144A1 (en) | 2007-08-10 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin |
| TR201901497T4 (tr) | 2008-04-29 | 2019-02-21 | Bioarctic Ab | Alfa-sinüklein ile ilişkili bozukluklar için terapötik ve teşhis yöntemlerinde kullanıma yönelik antikorlar ve aşılar. |
| EP2949666B1 (en) * | 2008-12-19 | 2018-12-19 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
| AU2010233187B2 (en) | 2009-04-09 | 2015-10-08 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating degenerative disorders of the central nervous system |
| SI2539366T1 (en) * | 2010-02-26 | 2018-05-31 | Bioarctic Neuroscience Ab | PROTOTRIBRIL-RELATED APPEALS AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC METHODS FOR PARKINSON'S DISEASE, DEMONS WITH LEWY BODIES AND OTHER ALPHA-SYNUKLEINOPATHIES |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| GB201008682D0 (en) | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
| AU2011315181B2 (en) | 2010-10-11 | 2016-07-28 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
| LT2723379T (lt) | 2011-06-23 | 2018-10-25 | Biogen International Neuroscience Gmbh | Anti-alfa sinukleiną rišančios molekulės |
| JP2013059866A (ja) | 2011-09-12 | 2013-04-04 | Seiko Epson Corp | 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム |
| KR101600733B1 (ko) * | 2011-10-28 | 2016-03-09 | 프로테나 바이오사이언시즈 리미티드 | 알파-시누클레인을 인식하는 인간화된 항체 |
| AU2013286680B2 (en) | 2012-07-03 | 2018-07-05 | Washington University | Antibodies to tau |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| JP6499077B2 (ja) | 2012-10-25 | 2019-04-10 | ザ ジェネラル ホスピタル コーポレイション | アルツハイマー病と関連疾患の治療のための併用療法 |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| KR102399292B1 (ko) * | 2013-11-21 | 2022-05-17 | 에프. 호프만-라 로슈 아게 | 항-알파-시누클레인 항체 및 사용 방법 |
| US9732148B2 (en) | 2014-10-16 | 2017-08-15 | Genentech, Inc. | Anti-α-synuclein antibodies and methods of use |
| JP2018519358A (ja) | 2015-05-07 | 2018-07-19 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 神経変性疾患を処置する方法 |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| JP7078552B2 (ja) | 2016-06-02 | 2022-05-31 | メディミューン リミテッド | α－シヌクレインに対する抗体およびその使用 |
| EP3541836A1 (en) | 2016-11-15 | 2019-09-25 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
-
2015
- 2015-07-13 GB GBGB1512203.9A patent/GB201512203D0/en not_active Ceased
-
2016
- 2016-07-11 JO JOP/2016/0140A patent/JO3692B1/ar active
- 2016-07-12 KR KR1020257011170A patent/KR20250051158A/ko active Pending
- 2016-07-12 EP EP16738736.4A patent/EP3322722B1/en active Active
- 2016-07-12 RU RU2017145653A patent/RU2765303C2/ru active
- 2016-07-12 FI FIEP16738736.4T patent/FI3322722T3/fi active
- 2016-07-12 UA UAA201800664A patent/UA125501C2/uk unknown
- 2016-07-12 MX MX2018000504A patent/MX2018000504A/es unknown
- 2016-07-12 TN TNP/2018/000005A patent/TN2018000005A1/en unknown
- 2016-07-12 MY MYPI2017001926A patent/MY194944A/en unknown
- 2016-07-12 PT PT167387364T patent/PT3322722T/pt unknown
- 2016-07-12 AU AU2016292896A patent/AU2016292896B2/en active Active
- 2016-07-12 JP JP2018501163A patent/JP7012004B2/ja active Active
- 2016-07-12 HU HUE16738736A patent/HUE071541T2/hu unknown
- 2016-07-12 PE PE2018000066A patent/PE20181049A1/es unknown
- 2016-07-12 CN CN201680039417.6A patent/CN107709361A/zh active Pending
- 2016-07-12 EP EP25154059.7A patent/EP4582144A3/en active Pending
- 2016-07-12 CR CR20180021A patent/CR20180021A/es unknown
- 2016-07-12 US US15/207,859 patent/US10800836B2/en active Active
- 2016-07-12 RS RS20250497A patent/RS66840B1/sr unknown
- 2016-07-12 ES ES16738736T patent/ES3028882T3/es active Active
- 2016-07-12 TW TW105121902A patent/TWI729992B/zh active
- 2016-07-12 MA MA42439A patent/MA42439B1/fr unknown
- 2016-07-12 WO PCT/EP2016/066476 patent/WO2017009312A1/en not_active Ceased
- 2016-07-12 EA EA201792616A patent/EA036499B1/ru not_active IP Right Cessation
- 2016-07-12 CR CR20230300A patent/CR20230300A/es unknown
- 2016-07-12 AR ARP160102110A patent/AR105336A1/es unknown
- 2016-07-12 LT LTEPPCT/EP2016/066476T patent/LT3322722T/lt unknown
- 2016-07-12 KR KR1020177037733A patent/KR102793383B1/ko active Active
- 2016-07-12 CN CN202210997939.4A patent/CN115925921A/zh active Pending
- 2016-07-12 SI SI201631902T patent/SI3322722T1/sl unknown
- 2016-07-12 DK DK16738736.4T patent/DK3322722T3/da active
- 2016-07-12 GE GEAP201614670A patent/GEP20207151B/en unknown
- 2016-07-12 PL PL16738736.4T patent/PL3322722T3/pl unknown
- 2016-07-12 HR HRP20250624TT patent/HRP20250624T1/hr unknown
-
2017
- 2017-11-14 US US15/812,251 patent/US10358482B2/en active Active
- 2017-11-14 US US15/812,303 patent/US10358483B2/en active Active
- 2017-11-14 US US15/812,410 patent/US10358484B2/en active Active
- 2017-11-14 US US15/812,363 patent/US10364285B2/en active Active
- 2017-12-15 CO CONC2017/0012941A patent/CO2017012941A2/es unknown
- 2017-12-18 ZA ZA2017/08607A patent/ZA201708607B/en unknown
- 2017-12-22 IL IL256501A patent/IL256501B/en unknown
-
2018
- 2018-01-03 PH PH12018500016A patent/PH12018500016A1/en unknown
- 2018-01-09 CL CL2018000075A patent/CL2018000075A1/es unknown
- 2018-01-11 NI NI201800006A patent/NI201800006A/es unknown
- 2018-01-11 SV SV2018005612A patent/SV2018005612A/es unknown
- 2018-01-11 DO DO2018000013A patent/DOP2018000013A/es unknown
- 2018-01-12 EC ECIEPI20182645A patent/ECSP18002645A/es unknown
- 2018-01-12 MX MX2023009483A patent/MX2023009483A/es unknown
-
2019
- 2019-06-17 US US16/443,225 patent/US10647764B2/en active Active
- 2019-06-17 US US16/443,249 patent/US10640554B2/en active Active
- 2019-06-17 US US16/443,187 patent/US10647763B2/en active Active
-
2020
- 2020-06-08 US US16/895,471 patent/US11524995B2/en active Active
- 2020-08-27 US US17/004,447 patent/US11421024B2/en active Active
- 2020-11-03 US US17/088,307 patent/US11542323B2/en active Active
-
2021
- 2021-08-24 JP JP2021136539A patent/JP7138322B2/ja active Active
-
2022
- 2022-08-29 JP JP2022136108A patent/JP7608404B2/ja active Active
- 2022-11-22 US US17/992,403 patent/US20230312693A1/en active Pending
-
2024
- 2024-12-18 JP JP2024221962A patent/JP2025041734A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529634A5 (enExample) | ||
| RU2017145653A (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| JP5896993B2 (ja) | ヒトｇｄｆ８に対する抗体 | |
| JP5730020B2 (ja) | アミロイドーシスの処置および予防 | |
| KR102308493B1 (ko) | 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2021184731A5 (enExample) | ||
| KR102533675B1 (ko) | 타우 인식 항체 | |
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| CN109219615A (zh) | 识别tau的抗体 | |
| JP2017522903A5 (enExample) | ||
| SA515360253B1 (ar) | أجسام مضادة مُميزة لألفا سينوكلين | |
| US20100215650A1 (en) | Methods of treating dementia using a gm-csf antagonist | |
| TW201637667A (zh) | 治療或預防偏頭痛之方法 | |
| CN102089430A (zh) | 针对渐进性糖化终极产物受体（rage）的抗体及其用途 | |
| JP2016514668A (ja) | プロタンパク質コンベルターゼスブチリシンケクシン９型に結合するヒト抗原結合タンパク質 | |
| CN103429260B (zh) | 用于治疗神经疾病的人抗体及其诊断和治疗用途 | |
| JP2011510913A5 (enExample) | ||
| TW202100550A (zh) | 識別ｔａｕ之抗體 | |
| TW202019477A (zh) | BCMAxCD3抗體構建體之給藥方案 | |
| US20230030950A1 (en) | Treatment of neurodegenerative diseases using ultrasound and amyloid-beta antibodies | |
| TW201121568A (en) | Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof | |
| JP2020521745A (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| BR112021006123A2 (pt) | anticorpos anti-sinucleína | |
| JP2023538117A (ja) | 神経免疫疾患のためのｃｄ３／ｃｄ２５抗体 | |
| JP6560808B2 (ja) | 抗（＋）メタンフェタミンモノクローナル抗体 |